Tagged with similars

France Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the high-risk field despite the withdrawal of many industry players, the strategy to keep MS at the core of its business while developing next-generation treatments in areas like Alzheimer’s, and the important…

Opinion Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the US urges Congress to avoid restricting out-of-court drug patent settlements and to move away from anti-competitive practices that work to restrict patients access to generics and biosimilars.    Recent legislation introduced in the US Senate would…

Malaysia Click here to download the Healthcare & Life Sciences Review Malaysia 2018. After recent elections conducted in May 2018 saw Mahathir Mohamad returning as Prime Minister after 15 years to seal a historic victory, Malaysia is again back on its feet. Bolstered by well-established institutions, a fully-functional IP framework and strong…

Korea In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of the leading Contract Development Manufacturing Organisations (CDMO) in the market in only seven years. Dr Kim also provides his assessment…

Malaysia How Malaysia is setting itself up to provide biosimilars across the Islamic world as well as Asia.   Inno Bio Ventures, a Malaysian state-owned company originally set up to create drug security by ensuring that the country was self-sufficient in terms of medicine supply, has been making its first moves…

Malaysia Tan Sri Rahman Mamat, chairman of Inno Bio Ventures, provides his vision for biosimilars’ potential in Malaysia, and the progress the company has made in laying the foundations to make Malaysia an export hub for biological products in the future.   There is a strong potential for exporting biosimilars [from…

France Catherine Bourrienne-Bautista, Déléguée générale of the GEMME (L’association Genérique Même Medicament, France’s generics and biosimilars association), provides her take on the state of the generics and biosimilars industry in France. Bourrienne-Bautista offers her thoughts on the 8th edition of the Strategic Council of Health Industries (CSIS) and outlines a plan…

Algeria Radwa Terbeche, general manager of Amgen in Algeria discusses the potential for biosimilars in Algeria and the company’s role in developing a local clinical research infrastructure.   What has been your journey to becoming country manager of Amgen Algeria? By education I am a pharmacist specialized in industry. After graduating,…

Algeria Sofiane Achi of El Kendi, one of Algeria’s leading pharma manufacturers, discusses the fresh ideas he has brought back to the company following a stint at Boehringer Ingelheim, manufacturing upgrades, and the country’s readiness for biosimilars. You decided to return to a company that you already know very well. How…

Spain Reig Jofre’s Ignasi Biosca outlines recent changes at the Spanish family-owned company, preserving its original ethos, portfolio development and internationalization plans. Can you update us on some of the recent changes at Reig Jofre? “The family still maintains 72 percent of the shares of the company so the original corporate…

Turkey Hakan Koçak, CEO–general manager of Koçak Farma, a company with 47 years in the pharmaceutical industry and the biggest production facility in Turkey, gives a thorough insight into Koçak Farma’s background, with their ground-breaking biosimilars as the leaders in the area of oncology with 85 products approved in Turkey, in…

Spain Timmo Andersen, general manager of Boehringer Ingelheim in Spain, explains how the affiliate has managed to achieve market-leading growth rates, the challenges and opportunities of the Spanish pharma market, and why BI is investing heavily in a new facility in Spain.   Boehringer Ingelheim in Spain grew an impressive 9…